↑  Read the latest from the desks  ·  fresh intelligence, published daily✦Quiet reading✦No ads, ever

✦Corporate brand & media services✦Made in Virginia Beach since 1997✦

Picard Medical: Rotting at the dock (four or more warning signs)Rotting at the dock

Picard Medical $PMI

Grew revenue 12.5% in FY2025 to $5 million, operating margin -268% against a 1.2% median for surgical & medical instruments & apparatus, equity 16.8% of assets.

Last filing10-Q, 16 Nov 2026

Next year, 80%$4M–$7M
Growth, on the year12.5%
Operating margin−268.4%
Equity of assets16.8%
Your call, sealedNext year’s revenue, your range. Sealed now, graded when the annual report lands.
Edgarette’s full reading · exposure, experience, soundness, credibility, range

🫧 Edgar looked up Picard Medical, Inc. ($PMI). Last filing: 10-Q, 2026-11-16. 39 event filings (8-K) in the past twelve months.

🔖 Exposure: revenue $4.9M (FY2025). Experience: revenue up 12.5% on the year; operating margin -268.4%, up from -312.3%. Soundness: equity 16.8% of assets, return on equity -712.6%. Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $4.1M and $7.3M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -268.4% against a 1.2% median; growth 12.5% against 11.6%.

Read from its own SEC filings · nothing written, nothing inferred

Picard Medical, Inc. against its own record and its peers
Operating marginPeer median 1.2%-268.4%Revenue, on the yearPeer median 11.6%12.5%Equity of assetsPeer median 52.9%16.8%Return on equityPeer median -2.3%-712.6%Gold tick: the median of 55–59 peers with $50M+ revenue in surgical & medical instruments & apparatus

Cash

Cash flow (op · inv · fin · free)−$16M · — · $27M · —
Investment book (cash · short · long)$7M · — · — · current ratio 1.11

The figures, as filed

Fiscal year end2025-12-31
Revenue$5M
Revenue, on the year12.5%
Revenue, a year over the record—
Operating margin−268.4%
Operating margin, prior year−312.3%
Net margin−546.6%
Research and development$3M · 61.7% of revenue
Total debt—
Equity of assets16.8%
Return on equity−712.6%
Payout of profit—
Dividend per share—
Earnings per share$-0.75
Book value per share$0.10
Revenue per share$0.14
Shares outstanding36,233,084
Audited years read2

Peers: the median of 60 filers with $50M+ revenue in surgical & medical instruments & apparatus.

Classic signals · fiscal 2025Altman Z″ -14.26 distress zone 1968Piotroski F 4 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals -65.4% earnings backed by cash 1996DuPont ROE needs net income, revenue and two years of assets and equity

What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →

Health HarborPicard Medical sails as Rotting at the dock4 warning signs

Health watch · 12 monthsExchange listing notice or transfer ×3Late quarterly report noticeDirector or officer change ×4

Versus peersoperating margin −268.4% vs a 1.2% median · revenue growth 12.5% vs 11.6% 60 surgical & medical instruments & apparatus filers

Trend · last year to this▲operating margin −312.3% → −268.4% · ▲revenue $4.4M → $4.9M

See all 71 surgical & medical instruments & apparatus companies on POPS4 sorted from the newest ship to the boat at the dock
#CompanyConditionOperating marginRevenue growthSales
1New shipLemaitre VascularLMATNew ship27.2%13.5%$249.6M
2New shipDexcomDXCMNew ship19.6%15.6%$4.7B
3New shipStrykerSYKNew ship19.5%11.2%$25.1B
4New shipMedlineMDLNNew ship7.8%11.5%$28.4B
5Sound shipResMedRMDSound ship33.4%9.9%$5.7B
6Sound shipWest Pharmaceutical ServicesWSTSound ship19.0%6.3%$3.1B
7Sound ship3M CompanyMMMSound ship18.6%1.5%$24.9B
8Sound shipBoston ScientificBSXSound ship18.0%19.9%$20.1B
9Sound shipInsuletPODDSound ship17.5%30.7%$2.7B
10Sound shipInterpace BiosciencesIDXGSound ship10.5%−17.5%$38.7M
11Sound shipInfusystem HoldingsINFUSound ship8.3%6.4%$143.4M
12Sound shipNephrosNEPHSound ship6.1%32.7%$18.8M
13Sound shipAngioDynamicsANGOSound ship−12.5%9.5%$320.2M
14Sound shipBluejay DiagnosticsBJDXSound ship−3741.5%—$0.2M
15Sound shipModular MedicalMODDSound ship——$0.0M
16Weathered boatMicrobot MedicalMBOTWeathered boat782.8%−88.5%$0.1M
17Weathered boatPro-DexPDEXWeathered boat16.8%16.5%$77.5M
18Weathered boatSanuwave HealthSNWVWeathered boat11.2%35.0%$44.1M
19Weathered boatMiniMed GroupMMEDWeathered boat−6.1%14.3%$3.1B
20Weathered boatiRhythm HoldingsIRTCWeathered boat−7.7%26.2%$747.1M
21Weathered boatSI-Bone, Inc.SIBNWeathered boat−11.1%20.2%$200.9M
22Weathered boatNovoCure LimitedNVCRWeathered boat−23.5%8.3%$655.4M
23Weathered boatIntegra Lifesciences HoldingsIARTWeathered boat−30.2%1.5%$1.6B
24Weathered boatProcept BioRoboticsPRCTWeathered boat−33.7%37.2%$308.1M
25Weathered boatBeta BionicsBBNXWeathered boat−71.5%53.9%$100.3M
26Weathered boatenVVeno MedicalNVNOWeathered boat−24566.5%−83.3%$0.0M
27Weathered boatAutonomix MedicalAMIXWeathered boat——$0.0M
28Weathered boatOdyssey HealthODYYWeathered boat——$0.0M
29Old boatGlucotrackGCTKOld boat1685.6%378.3%$0.2M
30Old boatTeleflex IncorporatedTFXOld boat5.9%17.2%$2.0B
31Old boatAccuray IncorporatedARAYOld boat−6.6%−12.3%$401.9M
32Old boatSkinHealth SystemsSKINOld boat−6.9%−10.0%$300.8M
33Old boatSonoma PharmaceuticalsSNOAOld boat−12.6%36.7%$19.5M
34Old boatCarlsmedCARLOld boat−60.5%85.9%$50.5M
35Old boatCVRxCVRXOld boat−90.5%10.4%$56.7M
36Old boatOrchestra BioMed HoldingsOBIOOld boat−154.7%1169.2%$33.5M
37Old boatProfound MedicalPROFOld boat−256.3%50.7%$16.1M
38Old boatIntelligent Bio SolutionsINBSOld boat−299.1%38.1%$4.2M
39Old boatTenon MedicalTNONOld boat−324.3%20.4%$3.9M
40Old boatBeyond AirXAIROld boat−378.2%107.3%$7.7M
41Old boatInspireMDNSPROld boat−552.6%28.1%$9.0M
42Old boatFemasysFEMYOld boat−767.0%40.8%$2.3M
43Old boatHarvard Apparatus Regenerative TechnologyHRGNOld boat−982.2%63.7%$0.7M
44Old boatSeaStar Medical HoldingICUOld boat−986.6%814.1%$1.2M
45Old boatLucid DiagnosticsLUCDOld boat−1054.8%8.3%$4.7M
46Old boatProfusaPFSAOld boat−4500.0%—$0.1M
47Old boatVivosRDGLOld boat−4628.7%144.3%$0.1M
48Old boatCO-DiagnosticsCODXOld boat−8058.8%−84.1%$0.6M
49Old boatPulse BiosciencesPLSEOld boat−21982.6%—$0.3M
50Old boatPAVmedPAVMOld boat−30712.7%−97.6%$0.1M
51Old boatStimCell EnergeticsSTMEOld boat—−100.0%$0.0M
52Old boatFractyl HealthGUTSOld boat—−100.0%$0.0M
53Old boatGlobal Innovative PlatformsGIPLOld boat——$0.0M
54Old boatAdagio Medical Holdings, Inc.ADGMOld boat—−100.0%$0.0M
55Rotting at the dockBiotricityBTCYRotting at the dock10.6%16.0%$16.0M
56Rotting at the dockPremier Air Charter HoldingsPREMRotting at the dock−8.5%53.6%$31.9M
57Rotting at the dockSS Innovations InternationalSSIIRotting at the dock−19.3%105.7%$42.5M
58Rotting at the dockNeuroneticsSTIMRotting at the dock−21.1%99.2%$149.2M
59Rotting at the dockNexGelNXGLRotting at the dock−29.3%31.5%$11.4M
60Rotting at the dockCytosorbentsCTSORotting at the dock−39.8%4.1%$37.1M
61Rotting at the dockTela BioTELARotting at the dock−42.0%15.8%$80.3M
62Rotting at the dockSpectral AIMDAIRotting at the dock−43.8%−33.6%$19.6M
63Rotting at the dockNuo TherapeuticsAURXRotting at the dock−76.0%142.7%$3.3M
64Rotting at the dockInvo FertilityIVFRotting at the dock−105.8%4.3%$6.8M
65Rotting at the dockVivos TherapeuticsVVOSRotting at the dock−114.1%16.0%$17.4M
66Rotting at the dockDarioHealthDRIORotting at the dock−163.9%−17.3%$22.4M
67Rotting at the dockPicard MedicalPMI · this companyRotting at the dock−268.4%12.5%$4.9M
68Rotting at the dockOsr HealthOSRHRotting at the dock−631.0%−17.7%$2.9M
69Rotting at the dockPetVivo HoldingsPETVRotting at the dock−793.9%0.8%$1.1M
70Rotting at the dockSintx TechnologiesSINTRotting at the dock−1053.1%−64.7%$1.0M
71Rotting at the dockFlyte AviationVJETRotting at the dock−2581.6%95.0%$0.8M

From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.

Tied up at the dock.

🌊 Visit the Bay →
The warning signs
  • Filed late quarterly report notice in the last 12 months
  • Operating cash flow was negative (-$15.7M in FY2025)
  • Operating loss a margin of -268.4% in FY2025
  • Revenue is hard to predict its 80% range is ±28%

Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.

Recent filings
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.

Try InstagramSpriteHokaDisneyGatoradee.l.f.

Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·

1 · Follow

Follow their filings

Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.

On Bluesky: follow Edgar & Edgarette.

2 · Price it

A new leader’s rebrand and launch

Priced live by the same engine as our estimator, from the catalogue at wholesale.

Price the printing · Open the full estimator

✦ Build the kit yourself
3 · Confirm

Check it with Jenny

Most buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.

Jenny Huang Goodman MPA MSc MHSA, Principal

Book a time info@pops4.com
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked

Clean data. No ads. Not now, not later.

Nine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.

Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Free to reuse with credit · CC BY 4.0 · how the boards are built
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.